Emergent BioSolutions CEO Robert Kramer retires; Haywood Miller named interim CEO

Emergent BioSolutions Inc.

Robert Kramer resigned as President/CEO and director effective June 24, 2023; will advise until Aug 1.
Haywood Miller, managing director at Berkeley Research Group, appointed interim CEO immediately.
Miller receives $125K/month cash compensation until permanent CEO is named or June 24, 2024.
Board to conduct search for permanent CEO with assistance from executive search firm.
Company highlights 2023 transformation including sale of travel health business and ACAM2000 contract extension.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Haywood Miller

interim Chief Executive Officer

EBS · Emergent BioSolutions Inc.

Effective: 2023-06-24
Filed: June 27, 2023, 7:59 PM ET

On June 24, 2023, the Board appointed Haywood Miller of Berkeley Research Group to serve as a non-employee interim Chief Executive Officer, effective immediately, until the Board’s search for a permanent Chief Executive Officer is completed.

Departed

Robert G. Kramer Sr.

President and Chief Executive Officer

EBS · Emergent BioSolutions Inc.

Effective: 2023-06-24
Successor: Haywood Miller
Filed: June 27, 2023, 7:59 PM ET

On June 23, 2023, Robert G. Kramer Sr. notified the Board of Directors (the “Board”) of Emergent BioSolutions, Inc. (the “Company”) of his intent to retire from the Company on August 1, 2023 and to resign from his positions as President and Chief Executive Officer and as a director, effective June 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Haywood Miller was appointed as interim Chief Executive Officer at Emergent BioSolutions Inc..

Action: appointed
Role: interim Chief Executive Officer

Exact text from the filing

On June 24, 2023, the Board appointed Haywood Miller of Berkeley Research Group to serve as a non-employee interim Chief Executive Officer, effective immediately, until the Board’s search for a permanent Chief Executive Officer is completed.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert G. Kramer Sr. resigned as President and Chief Executive Officer at Emergent BioSolutions Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On June 23, 2023, Robert G. Kramer Sr. notified the Board of Directors (the “Board”) of Emergent BioSolutions, Inc. (the “Company”) of his intent to retire from the Company on August 1, 2023 and to resign from his positions as President and Chief Executive Officer and as a director, effective June 24, 2023.

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.